
    
      A Phase 2, multicenter, open-label, randomized clinical trial. The study was to evaluate the
      efficacy and safety of ACP-196 plus nab-paclitaxel/gemcitabine compared with
      nab-paclitaxel/gemcitabine in subjects who have previously untreated metastatic pancreatic
      cancer.
    
  